Glucotoxicity and Acute Exercise

The Effects of Hyperglycaemia on the Response to Acute Exercise

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01771614

Enrollment

Registered

2013-01-18

Start date

2016-08-31

Completion date

2017-01-31

Last updated

2018-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes, Type 2 Diabetes

Keywords

Glucotoxicity, Exercise, Beta-cell function

Brief summary

Experimental hyperglycemia (5 hours) will be induced via a constant- or fluctuating-rate glucose infusion to establish different patterns of glycemia in healthy individuals. The effects of these acute models of hyperglycemia on the adaptations to a single aerobic exercise bout will be tested. Changes in pancreatic endocrine function, insulin sensitivity, endothelial function, and oxidative stress will be measured.

Interventions

BEHAVIORALExercise

PROCEDUREHyperglycemia

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

for participation: * Male * Age 18-50 years * Body Mass Index 19-30 kg/m2 * Generally healthy

Exclusion criteria

for participation: * Regular use of anti-inflammatory medication * Smokers * More than 2 kg weight change in prior 6 months * Previous weight loss surgery * Cancer, or evidence of chronic haematological, pulmonary, cardiac, hepatic, renal, or gastrointestinal disease * Evidence of diabetes * Engaged in moderate or vigorous activity on more than 5 days per week

Design outcomes

Primary

Measure	Time frame	Description
Pancreatic endocrine function	0, 6, 7, 9, and 24 hours	The plasma insulin, C-peptide, and glucagon responses to a 0.33 g/kg intravenous glucose tolerance test (IVGTT) will be measured. In each trial, the IVGTT will be performed at T = 0, 6, 7, 9, and 24 hours.

Secondary

Measure	Time frame	Description
Glucose tolerance	0, 6, 7, 9, and 24 hours	Glucose tolerance will be measured during an IVGTT in each trial at T = 0, 6, 7, 9, and 24 hours.
Endothelial function	0, 6, 7, 9, and 24 hours	Blood flow and flow-mediated dilation by Doppler ultrasound will be measured in each trial at T = 0, 6, 7, 9, and 24 hours.
Oxidative stress	24 hours	Urine will be collected over the whole 24-hour period of each trial and 8-iso Prostaglandin F3α will be measured.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026